Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company designs, develops, and seeks to commercialize tests that detect and analyze genetic material, positioning itself to make sophisticated molecular testing faster, cheaper, and more accessible than traditional centralized laboratory methods. Investors follow the stock for its proprietary PCR technology, its point-of-care ambitions, and its efforts to build a global commercial footprint in emerging markets. From what I see, the focus on decentralization stands out as a core differentiator in this space.
Co-Diagnostics was founded in 2013 by Dr. Brent C. Satterfield and Dwight H. Egan, who has served as its chief executive officer. The company completed its initial public offering (IPO) and began trading on the NASDAQ in July 2017. Its founding premise was a proprietary approach to PCR test design, including algorithms and reagents aimed at reducing costs and improving accuracy compared with competing PCR systems. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PCR, or polymerase chain reaction, is a laboratory technique used to amplify small amounts of DNA or RNA so that a specific target — such as a virus or bacterium — can be detected. Co-Diagnostics' early intellectual property centered on mathematical algorithms for designing tests and a technique known as "Co-Primers," intended to reduce false-positive and false-negative results.
Co-Diagnostics' business model combines reagent and test sales with a broader platform strategy. Its primary focus is the Co-Dx PCR platform, an integrated system that includes the Co-Dx PCR Pro instrument, a proprietary disposable test cup, and a mobile application. The system is designed to bring PCR testing out of central laboratories and into point-of-care and at-home settings.
The company's pipeline includes tests for respiratory conditions (such as influenza A/B, RSV, and COVID-19), tuberculosis (TB), and HPV, as well as assays for other infectious diseases. Beyond infectious disease testing, Co-Diagnostics has also explored applications in agricultural genetics and other non-medical genetic-marker detection. Historically, the company's revenue has come primarily from diagnostic kits and equipment, supplemented by grant funding from organizations such as the Bill & Melinda Gates Foundation and the U.S. National Institutes of Health. During the COVID-19 pandemic, demand for its tests drove a significant revenue spike; in subsequent years, revenue declined sharply as pandemic-related demand faded.
Co-Diagnostics competes in the molecular diagnostics market against larger, well-capitalized players, but it differentiates itself through a lower-cost, decentralized testing model. A central element of its strategy is international expansion through joint ventures. Through CoSara, its joint venture in India, the company has pursued regulatory clearances and local manufacturing for its PCR instruments and tests, with a particular emphasis on tuberculosis — a disease for which India represents one of the world's largest testing markets. Through CoMira, a joint venture with a local partner in Saudi Arabia, Co-Diagnostics aims to establish domestic molecular diagnostics manufacturing and distribution across the broader Middle East and North Africa (MENA) region.
Co-Diagnostics attracts investor attention primarily for its long-term growth potential rather than its current financial profile. The company's proprietary PCR technology and its push to enable decentralized, point-of-care testing address a genuine market need for faster and more affordable diagnostics, particularly in resource-limited settings. Its alignment with World Health Organization (WHO) guidance favoring near point-of-care molecular tuberculosis testing supports the relevance of its TB program. Its joint-venture model offers a capital-efficient route to local manufacturing and distribution in high-growth markets. Investors also monitor the company's regulatory progress, including FDA submissions for its respiratory tests, and its evolving use of artificial intelligence in assay design and data analysis.
Co-Diagnostics carries the risk profile typical of a development-stage healthcare company. Its revenue base has been small in recent years, and the company has reported recurring operating losses as it invests in research, clinical studies, and manufacturing ahead of broad commercialization. Management has stated that additional capital may be required to fund its plans, and financing activity can dilute existing shareholders. The company's flagship Co-Dx PCR platform and its associated tests are subject to regulatory review by the FDA and other authorities and are not yet broadly available for sale in the United States. Regulatory timelines can shift, and approval is not guaranteed. The business also faces competition from larger diagnostics firms, exposure to evolving reimbursement and regulatory environments, and the risk that commercialization in emerging markets proceeds more slowly than anticipated.
Co-Diagnostics, Inc. is a molecular diagnostics company built around a proprietary PCR platform intended to make sophisticated genetic testing more portable, affordable, and accessible. While its current financial profile reflects the early, investment-heavy phase of a development-stage business, its technology, regulatory pipeline, and joint-venture strategy in India and the MENA region give it a distinctive market position. For investors, the stock represents an opportunity to follow a company pursuing decentralized diagnostics in both developed and emerging markets — alongside the risks inherent in a pre-commercial, capital-intensive business model.
In my own workflow, I frequently use Tickeron’s AI Screener to quickly compare companies like this one against peers based on fundamentals, trends, and patterns. It helps surface relevant ideas without sifting through endless data manually, and it has become a reliable part of how I evaluate development-stage names in diagnostics and beyond.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where CODX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CODX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA
Industry MedicalNursingServices